NCT04683939 - Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in Patients With Unresectable or Metastatic CLDN18.2-positive Gastric, Pancreatic, Ovarian and Biliary Tract Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 18, 2022

Primary Completion Date

July 24, 2023

Study Completion Date

July 24, 2023

Conditions

Solid TumorGastric CancerGastroesophageal Junction AdenocarcinomaEsophageal AdenocarcinomaPancreatic CancerBiliary Tract CancerCholangiocarcinomaMetastatic Cancer

Interventions

DRUG

BNT141

Intravenous (IV)

DRUG

Nab-paclitaxel

DRUG

Gemcitabine

Trial Locations (7)

77030

MD Anderson Cancer Center, Houston

78229

NEXT Oncology, San Antonio

START, San Antonio

91010

City of Hope, Duarte

H2X3E4

University of Montreal - Centre Hospitalier de l´Université de Montréal, Montreal

M5B1W8

St. Michaels Hospital, Toronto

M5G1X5

Princess Margaret Cancer Centre - University Health Network, Toronto